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The twomain phenotypes of inﬂammatory bowel disease (IBD)—Crohn’s disease (CD) and ulcerative colitis (UC)—are chronic intestinal
inﬂammatory disorders with a complex genetic background. Using a three-stage design, we performed a functional candidate-gene anal-
ysis of innate immune pathway in IBD. In phase I, we typed 354 SNPs from 85 innate immunity genes in 520 Dutch IBD patients (284
CD, 236 UC) and 808 controls. In phase II, ten autosomal SNPs showing association at p < 0.006 in phase I were replicated in a second
cohort of 545 IBD patients (326 CD, 219 UC) and 360 controls. In phase III, four SNPs with p< 0.01 in the combined phase I and phase II
analysis were genotyped in an additional 786 IBD samples (452 CD, 334 UC) and 768 independent controls. Joint analysis of 1851 IBD
patients (1062 CD, 789 UC) and 1936 controls demonstrated strong association to the IL18RAP rs917997 SNP for both CD and UC (pIBD
1.9 3 108; OR 1.35). Association in CD is independently supported by the Crohn’s disease dataset of the Wellcome Trust Case Control
Consortium (imputed SNP rs917997, p ¼ 9.19 3 104). In addition, an association of the CARD9 rs10870077 SNP to CD and UC was
observed (pIBD ¼ 3.25 3 105; OR 1.21). Both genes are located in extended haplotype blocks on 2q11-2q12 and 9q34.3, respectively.
Our results indicate two IBD loci and further support the importance of the innate immune system in the predisposition to both CD
and UC.The inﬂammatory bowel diseases (IBDs) are common,
chronic, gastrointestinal inﬂammatory disorders that
comprise two major forms—Crohn’s disease (CD [MIM
266600]) and ulcerative colitis (UC [MIM 191390]). Their
combined prevalence is estimated at 100–200/100,000 in
developed countries.1,2 The etiology of CD and UC is com-
plex and consists of an impaired immune response to the
commensal bacterial ﬂora in a genetically susceptible host.
In 2001 the NOD2 gene (also known as CARD15 [MIM
605956]) on chromosome 16 was identiﬁed as the ﬁrst
susceptibility gene for CD.3 NOD2 is a part of the innate
immunity system and belongs to the family of pattern-rec-
ognition receptors (PRRs) that recognize bacterial peptido-
glycans; it is among one of the ﬁrst lines of defense against
microbial ﬂora in the gastrointestinal tract. Since the dis-
covery of NOD2 as a CD susceptibility gene, the role of
the innate immune system in IBD has been studied exten-
sively, and mutations in a number of genes of the innate
immunity pathway have been found to be associated
with CD susceptibility.3–5 The most promising results sug-
gest an association for NOD1 (MIM 605980) and Toll-like
receptor 4 (TLR4) (MIM 603030) with CD.4,6
Whole-genome association studies performed during re-
cent years have been remarkably successful in providing
better insight into the genetic background of CD. Recently1202 The American Journal of Human Genetics 82, 1202–1210, Maydescribed CD susceptibility variants in IL23R (MIM
607562), ATG16L1 (MIM 610767), and IRGM (MIM
608212), at 5p13.1 and other loci, have been successfully
replicated in multiple independent populations.7–11 How-
ever, all these ﬁndings together still only partly explain the
genetic background of CD, andmany reported associations
require further replication and validation. So far, no con-
vincing genetic associations have been established for UC.
In this study, we performed an extensive candidate-path-
way genetic screen for IBD susceptibility by using a multi-
stage case-control design. We aimed to investigate the
innate immunity pathway, including the pattern-recogni-
tion receptor genes (PRRs) and their downstream tar-
gets.12–17 The study included the Toll-like receptor (TLR)
pathway with the TLR genes 1 to 10 (MIM 601194,
603028, 603029, 603030, 603031, 605403, 300365,
300366, 605474, and 606270, respectively), molecules im-
portant for recognizing lipopolysaccharides by distinct
TLRs (CD14 [MIM 158120] and LY96 [MIM 605243]),
downregulators of TLR activity (TOLLIP [MIM 606277]
and PPARG [MIM 601487] and SIGIRR [MIM 605478]),
adaptor molecules (MYD88 [MIM 602170], TICAM1
(TRIF) [MIM 607601], TICAM2 [MIM 608321], and TIRAP
[MIM 606252]), downstream effectors of MYD88 (TRAF6
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606883]), and downstream effectors of TRIF (CFLPR [MIM
603599], FADD [MIM 602457], TBK1 [MIM 604834], and
all 12 components of the NF-kb pathway). The Toll-inde-
pendent recognition of pathogen-associated molecular
patterns (PAMPs) included genes involved in delivery of
muramyl dipeptides into the intracellular space (PEPT1
[SLC15A1] [MIM 600544] and PEPT2 [SLC15A2] [MIM
602339]), downstream pathways of NODs (APAF1 [MIM
602233], RIPK2 [MIM 603455], CARD9 [MIM 607212],
and GRIM19 [MIM 609435]), inhibitors of NOD signaling
(CARD6 [MIM 609986], CARD7 [MIM 606636], CARD12
[MIM 606831], CIAS1 [MIM 606416]), and other genes
involved in PAMPs recognition. We also included inter-
feron regulatory factors that are activated by the pathways
described above and a number of cytokines and their re-
ceptors (IL-1, 2, 12, 15, 18, 23, and IFN1A and B) that are
important in innate immunity. Two well-described PRR
genes—NOD1 and NOD2—have been previously studied
in IBD populations and were therefore not included in
this study.18 Some candidate genes involved in the path-
way were excluded from our list as a result of a lack of hap-
lotype tagging SNPs in the gene region (e.g., IRAK1).
In total, we included 85 genes located in 74 genomic
regions in our screen (Table S1 in the Supplemental Data
available online). Each investigated locus included the
coding part of a gene and at least 3 kb of the promoter
region and 2 kb of the 30 end. The ﬂanking region was
extended (to ~20 kb) for ~10% of the genes that are located
either in extended haploblocks or in SNP-desert regions.
Tag SNPs were selected with the Tagger program and the
following parameters: r2 > 0.8, minor allele frequency
(MAF) > 0.1, multimarker tagging. SNP genotyping was
performed with the GoldenGate assay on an Illumina
BeadStation 500GX (Illumina, San Diego, USA). Analysis
was performed with Bead Studio software. As quality-con-
trol measures, samples showing a mismatch between X
chromosome genotypes and stated gender and duplicate
samples were removed; genotype call rate and Hardy-
Weinberg equilibrium within controls and cases were
determined. Only samples with a call rate above 95%
were included in further analysis. Initially, 455 tag SNPs
were included in this study. A large number of SNP assays
failed (n ¼ 101, 22%), in part because of an error in oligo-
nucleotide synthesis at Illumina’s manufacturing facility
(the company subsequently accepted responsibility and
reimbursed us). In addition, we excluded nonpolymorphic
and dubiously clustered SNPs (Table S2), resulting in 354
successfully genotyped SNPs that we used for further anal-
ysis. Three SNPs showed strong deviation from Hardy-
Weinberg equilibrium in the controls (pHWE < 0.002) and
were discarded from further analysis.
The population studied consisted of 1851 IBD patients
(CD 1062, UC 789). IBD patients were recruited from the
VU University Medical Center, Amsterdam (n ¼ 520),19
University Medical Center Groningen (n ¼ 545)20, and
the Academic Medical Center, Amsterdam (n ¼ 786)21,
the Netherlands, and were all of European descent. AllThe Ampatients were diagnosed according to accepted clinical, en-
doscopic, radiological, and histological criteria2; 66.9% of
CD patients and 45.8% of UC patients were females. The
control group (n ¼ 1936) comprised three independent
groups: (i) healthy blood donors from Amsterdam (n ¼
381) and Utrecht (n ¼ 427), the Netherlands22; (ii) healthy
spouses of patients included in different, non immune-
mediated projects in Utrecht (n¼ 360)23, and (iii) 768 con-
trols from the general-population-based Vlagtwedde/
Vlaardingen cohort (individuals of Dutch descent, Gronin-
gen and Rotterdam area) participating in the last survey in
1989 and 1990.24,25 Only individuals for whom at least
three out of four grandparents were born in the Nether-
lands were included in this study; 45.6% of controls were
females. All patients and controls gave informed consent,
and the study was approved by the ethics review commit-
tees of each of the participating hospitals. All DNA samples
and data in this study were handled anonymously. The
design of the study is illustrated in Table 1.
In phase I of the study, 520 IBD patients (284 CD, 236
UC) and 808 controls were successfully genotyped for
354 SNPs. The association was calculated by an allele fre-
quency test (1 df c2 test) and by a genotype frequency
test (2 df c2 test) (columns showing ‘‘p-allele’’ and ‘‘p-geno-
types’’ in Table S1). Hardy-Weinberg equilibrium was cal-
culated from a comparison of expected and observed geno-
types in 2 3 3 c2 tables (columns showing HWE controls
and HWE cases in Table S1). From the 74 genomic regions
included in the study, the strongest association was ob-
served with the rs7539625 SNP located in IL23R [MIM
607562] (pCD ¼ 2.63 3 105). The association for the
IL23R gene with CD has been well established.7,20,26,27 As-
sociation results for all SNPs included in the study are pre-
sented in Table S1.
We performed a haplotype analysis on all tested loci,
since the selection of tag SNPs was based on a multimarker
strategy and in order to recover information that was
missed due to failed SNPs. Haplotypes were investigated us-
ing the Haploview application.28 We observed an associa-
tion with nine genes on a haplotype level at p < 0.006,
which is the samep-value cut off we chose to use for the sin-
gle SNP analysis. All associated haplotypes, except one,
were located in the genes that also showed association on
a single SNP level with the same selected p-value cut-off
(p < 0.006). One locus – comprising the IL18 receptors on
chromosome 2q11-2q12 – was signiﬁcantly associated in
the haplotype analysis, but not at the single SNP level. We
observed that the haplotype including the rs2287037*G-
rs1035130*G-rs2241116*C and rs6706002*A alleles
occurred more frequently in IBD cases (26.1%) than in
controls (21.4%) (p ¼ 0.006).
We extensively investigated the haplotype structure of
the IL18R1-IL18RAP receptor locus using the HapMap
data.29 The IBD-associated haplotype is located in a block
with strong linkage disequilibrium (LD) expanding ~350
kb. This LD block includes four genes: the 30 parts of
IL1RL1 (MIM 601203), IL18R1 (MIM 604494), IL18RAPerican Journal of Human Genetics 82, 1202–1210, May 2008 1203
(MIM 604509) and 50 part of SLC9A4 (MIM 600531). Forty-
two SNPs have a single allele that is in perfect LD with our
associated haplotype in the HapMap data and can there-
fore tag this haplotype at a single SNP level. None of the
42 SNPs were typed in the current project (Supplementary
Table 1). However, one of these SNPs – rs917997 – was
tested on the set of Dutch controls for another of our
projects. In the 791 controls that were genotyped both
for the IL1RL1-IL18R1-IL18RAP-SLC9A4 haplotypes and
for the single SNP rs917997, the haplotype structure was
found to be similar to the HapMap data. We observed
that the associated haplotype rs2287037*G-rs1035130*G-
rs2241116*C-rs6706002*A was in perfect LD with the
rs917997*A allele and they are therefore perfect proxies
for each other (Table 2). Based on these ﬁndings, SNP
rs917997 was used for further replication of the IL1RL1-
IL18R1-IL18RAP-SLC9A4 locus.
We performed a replication study of the ten most
strongly associated autosomal genes identiﬁed by single
SNP- or haplotype analysis in either CD, UC or IBD (p <
0.006) in phase I. This replication was conducted on a sec-
ond, independent, IBD cohort (phase II). In genes where
two or more SNPs showed association, only the most sig-
Table 1. Control and Case Groups Included in the Study
Study Groups Dutch Cases Dutch Controls
Phase I: VUMC
Amsterdam
IBD n ¼ 520 Healthy blood donors
(n ¼ 808) from
Amsterdam (n ¼ 381)
and Utrecht (n ¼ 427)
284 CD
236 UC
Phase II: UMC
Groningen
IBD n ¼ 545 UMC Utrecht controls
(n ¼ 360)326 CD
219 UC
Phase III: AMC
Amsterdam
IBD n ¼ 786 Population controls from
Groningen area (n ¼ 768)452 CD
334 UC
Electronic Replication in the Imputed WTCCC Dataset
WTCCC IBD n ¼ 1748 WTCCC controls (n¼ 2938)
1748 CD
0 UC
Three independent case groups were recruited from the VU University
Medical Center (VUMC), Amsterdam, University Medical Center (UMC),
Groningen, and the Academic Medical Center (AMC), Amsterdam. Imputed
WTCCC data are publicly available online.1204 The American Journal of Human Genetics 82, 1202–1210, Maniﬁcantly associated SNP was used for further replication.
The IL23R gene was not included in the replication since
this gene has already been established as a risk factor for
IBD in the Dutch IBD cohort.20
Nine SNPs were tested in the second IBD cohort, com-
prising 545 Dutch IBD patients (326 CD and 219 UC)
from the University Medical Center Groningen20 and
360 independent controls (Table 3). Genotyping of all
polymorphisms was performed with TaqMan probes and
primers, using assays developed by Applied Biosystems,
and an ABI 7900HT system (Applied Biosystems, Nieuwer-
kerk a/d IJssel, the Netherlands). To ensure that the anno-
tation of C/G and T/A SNPs both on Taqman and Illumina
was performed on the same strand, we did additional Taq-
Man genotyping of 50 controls for rs8177676 T/A,
rs10418239 C/G and rs10870077 C/G. All the called con-
trol samples showed 100% concordance of the genotypes
obtained from the Taqman and Illumina platforms. The as-
sociation was calculated by allele frequency test (1 df c2
test). All SNPs were in HWE (pHWE > 0.05) in control
group.
Of the nine SNPs replicated in phase II, rs917997 showed
association in both the CD and UC cohorts (p ¼ 0.0002;
odds ratio [OR] 1.60 [95% CI: 1.25–2.04] and p ¼ 0.003;
OR 1.52 [95%CI: 1.15 – 2.00], respectively) (Table 3). Com-
bined analysis for rs917997 (either directly genotyped or
imputed from other SNPs) of the patient cohorts from
phases I and II showed association to the IL1RL1-IL18R1-
IL18RAP-SLC9A4 locus in both CD (p ¼ 1.20 3 105) and
UC (p¼ 4.503 105) (Table 3). After Bonferroni correction
for multiple testing of 354 SNPs, the association with
rs917997 remained signiﬁcant. In addition, the combined
analysis of phases I and II also showed association with
rs842647 in REL to UC (p ¼ 0.003; OR 0.78 [95% CI:
0.65–0.92]) rs10418239 in CARD8 to UC (p ¼ 0.004; OR
1.26 [95% CI: 1.08–1.48]) and with rs10870077 in
CARD9 to UC (p ¼ 0.003; OR 1.26 [95% CI: 1.08–1.47]).
To further conﬁrm the association of rs917997 and the
CARD8-rs10418239 and CARD9-rs10870077 SNPs, we per-
formed a third analysis (phase III) in which these three
SNPs were tested in an IBD cohort of 452 CD and 334
UC cases from Amsterdam and 768 population controls
from Groningen, the Netherlands.21 SNPs were genotyped
by Taqman as described above. Analysis of the phase IIITable 2. Linkage Disequilibrium between the rs2287037-rs1035130-rs2241116-rs6706002 haplotype block and the
rs917997*A Allele in 791 Dutch Control Samples
rs2287037 rs1035130 rs2241116 rs6706002 rs917997 Frequency Counts
G G C G G 0.397 626.6: 951.4
A A A A G 0.219 345.7: 1232.3
G G C A A 0.213 336.1: 1241.9
A G C G G 0.089 140.4: 1437.6
A A C A G 0.076 120.0: 1458.0
A total of 791 controls were typed for rs2287037-rs1035130-rs2241116-rs6706002 haplotypes and for single SNP rs917997 located in the IL18R1-IL18RAP
gene locus. All haplotypes above a frequency of 0.005 are shown. The rs917997*A allele and rs2287037*G-rs1035130*G-rs2241116*C-rs6706002*A
haplotype (in bold) tag the same haplotype and are therefore perfect proxies for each other.y 2008
l Phases I and II Cases Phases I and II
MAF P Value OR (95% CI)
0.169 0.25 1.12 (0.93–1.35)
0.332 0.189 0.91 (0.78–1.05)
0.282 1.20 3 105 1.43 (1.22–1.68)
0.128 0.07 0.83 (0.67–1.02)
0.468 0.15 1.11 (0.96–1.28)
0.105 0.22 1.16 (0.92–1.47)
0.414 0.32 1.08 (0.93–1.24)
0.124 0.78 1.03 (0.84–1.28)
0.356 0.38 1.07 (0.92–1.24)
0.246 0.04 0.85 (0.72–1.00)
0.173 0.19 1.15 (0.94–1.42)
0.298 0.003 0.78 (0.65–0.92)
0.284 4.50 3 105 1.44 (1.21–1.72)
0.139 0.36 0.91 (0.73–1.13)
0.500 0.003 1.26 (1.08–1.47)
0.112 0.08 1.25 (0.97–1.61)
0.419 0.24 1.10 (0.94–1.29)
0.152 0.02 1.31 (1.05–1.64)
0.395 0.004 1.26 (1.08–1.48)
0.248 0.09 0.86 (0.72–1.03)
0.170 0.13 1.13 (0.96–1.33)
0.317 0.01 0.85 (0.75 - 0.96)
0.282 2.82 3 107 1.43 (1.25–1.64)
0.133 0.08 0.86 (0.72–1.02)
0.482 0.008 1.17 (1.04–1.32)
0.108 0.07 1.20 (0.98–1.46)
0.416 0.18 1.09 (0.96–1.23)
0.136 0.12 1.15 (0.96–1.37)
0.372 0.03 1.15 (1.01–1.30)
0.247 0.02 0.85 (0.75–0.98)
ined analysis of phase I and II includes 1065 IBD samples (610
es).
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5Table 3. Replication of the Ten Associated SNPs from the Phase I Screen in the Phase II Cohort
Control Phase I Cases Phase I Control Phase II Cases Phase II Contro
Gene Name Minor Allele MAF MAF P Value OR (95% CI) MAF MAF P Value OR (95% CI) MAF
Crohn’s Disease
IKBKE rs12728136 A 0.143 0.188 0.010 1.40 (1.09–1.80) 0.178 0.151 0.182 0.82 (0.62–1.10) 0.154
REL rs842647 G 0.355 0.300 0.013 0.77 (0.63– 0.94) 0.354 0.365 0.679 1.05 (0.83–1.32) 0.354
IL18RAP rs917997a A 0.214 0.252 0.067 1.24 (0.99–1.55) 0.218 0.309 0.0002 1.60 (1.25 –2.04) 0.216
CARD6 rs10512747 A 0.157 0.110 0.006 0.67 (0.50–0.90) 0.138 0.146 0.691 1.07 (0.78–1.45) 0.151
CARD9 rs10870077 G 0.437 0.470 0.172 1.14 (0.94–1.39) 0.455 0.466 0.680 1.05 (0.84–1.3) 0.442
IL15RA rs8177676 A 0.088 0.111 0.116 1.30 (0.95–1.77) 0.101 0.1 0.973 1.00 (0.70–1.42) 0.092
CHUK rs11597086 C 0.386 0.456 0.004 1.33 (1.10–1.62) 0.419 0.375 0.096 0.83 (0.66–1.03) 0.396
LGP2 rs12600570 A 0.117 0.130 0.401 1.14 (0.85 –1.52) 0.129 0.118 0.539 0.90 (0.65–1.26) 0.121
CARD8 rs10418239 G 0.337 0.340 0.912 1.01 (0.83–1.24) 0.349 0.37 0.421 1.10 (0.88–1.37) 0.341
VISA rs8116776 A 0.283 0.217 0.002 0.07 (0.56–0.88) 0.266 0.274 0.757 1.04 (0.81–1.33) 0.278
Ulcerative Colitis
IKBKE rs12728136 A 0.143 0.214 0.0002 1.64 (1.26–2.12) 0.178 0.127 0.022 0.68 (0.48–0.95) 0.154
REL rs842647 G 0.355 0.302 0.038 0.79 (0.64– 0.99) 0.354 0.292 0.036 0.76 (0.58–0.98) 0.354
IL18RAP rs917997* A 0.214 0.271 0.010 1.37 (1.08–1.73) 0.218 0.298 0.003 1.52 (1.15–2.00) 0.216
CARD6 rs10512747 A 0.157 0.146 0.561 0.93 (0.69–1.23) 0.138 0.13 0.697 0.94 (0.66–1.34) 0.151
CARD9 rs10870077 G 0.437 0.515 0.003 1.37 (1.11–1.68) 0.455 0.483 0.359 1.12 (0.88–1.43) 0.442
IL15RA rs8177676 A 0.088 0.131 0.006 1.57 (1.14–2.15) 0.101 0.091 0.597 0.90 (0.60–1.37) 0.092
CHUK rs11597086 C 0.386 0.443 0.027 1.26 (1.03–1.55) 0.419 0.392 0.371 0.89 (0.70–1.14) 0.396
LGP2 rs12600570 A 0.117 0.169 0.003 1.55 (1.17–2.06) 0.129 0.133 0.861 1.04 (0.73–1.48) 0.121
CARD8 rs10418239 G 0.337 0.411 0.003 1.37 (1.11–1.69) 0.349 0.374 0.360 1.13 (0.87–1.45) 0.341
VISA rs8116776 A 0.283 0.233 0.031 0.77 (0.61–0.98) 0.266 0.266 0.995 1.00 (0.76–1.32) 0.278
Inflammatory Bowel Disease (Crohn’s Disease þ Ulcerative Colitis)
IKBKE rs12728136 A 0.143 0.200 0.0001 1.50 (1.22–1.84) 0.178 0.141 0.038 0.76 (0.59–0.98) 0.154
REL rs842647 G 0.355 0.300 0.003 0.78 (0.66 - 0.92) 0.354 0.336 0.439 0.93 (0.75 - 1.12) 0.354
IL18RAP rs917997* A 0.214 0.261 0.006 1.29 (1.08–1.55) 0.218 0.304 0.00007 1.56 (1.25–1.95 0.216
CARD6 rs10512747 A 0.157 0.126 0.027 0.78 (0.62–0.97) 0.138 0.139 0.931 1.01 (0.77–1.33) 0.151
CARD9 rs10870077 G 0.437 0.490 0.007 1.24 (1.06–1.45) 0.455 0.474 0.434 1.08 (0.89–1.31) 0.442
IL15RA rs8177676 A 0.088 0.120 0.008 1.41 (1.09–1.81) 0.101 0.097 0.781 0.95 (0.69–1.31) 0.092
CHUK rs11597086 C 0.386 0.450 0.001 1.30 (1.11–1.52) 0.419 0.383 0.122 0.86 (0.71–1.04) 0.396
LGP2 rs12600570 A 0.117 0.148 0.020 1.31 (1.05–1.65) 0.129 0.124 0.760 0.95 (0.72–1.27) 0.121
CARD8 rs10418239 G 0.337 0.372 0.066 1.16 (0.99–1.37) 0.349 0.372 0.329 1.10 (0.90–1.35) 0.341
VISA rs8116776 A 0.283 0.224 0.001 0.73 (0.61–0.88) 0.266 0.271 0.818 1.02 (0.83–1.27) 0.278
Phase I included 520 IBD samples (284 CD, 236 UC) and 808 controls; phase II included 545 IBD samples (326 CD, 219 UC) and 360 controls; the comb
CD, 455 UC) and 1168 controls. Allele call for C/G and T/A SNPs is annotated according to the TaqMan genotype calls.
a rs917997 was either genotyped directly or imputed from rs2287037*G-rs1035130*G-rs2241116*C-rs6706002*A haplotype (in the phase I IBD cas
data conﬁrmed the association of the IL18RAP SNP
rs917997 in CD (p ¼ 0.012; OR 1.27 [95% CI (1.05–
1.54)]) and showed a similar trend in UC (p ¼ 0.091; OR
1.20 [95% CI (0.97–1.48)]).Association of the CARD9 SNP
rs10870077 was also conﬁrmed in the phase III CD and
UC groups (Table 4). However, association of the CARD8
SNP rs10418239 and the REL – rs842647 was not observed
in the phase III cohort, although it remained moderately
signiﬁcant in the combined UC (CARD8) and UC and CD
(REL) dataset.
The combined analysis of 1851 IBD patients included in
phases I, II, and III (1062 CD and 789 UC samples; 1936
controls) showed strong association to rs917997 of the
IL1RL1-IL18R1-IL18RAP-SLC9A4 locus with both CD
(p ¼ 6.3 3 107; OR 1.36; 95% CI [1.21–1.54]) and UC
(p ¼ 2.46 3 105; OR 1.34; 95% CI [1.17–1.53]). SNP
rs10870077 in the CARD9 locus showed stronger associa-
tion with UC (p ¼ 4.03 3 105; OR 1.28; 95% CI [1.14–
1.44]) and moderate association with CD (p ¼ 0.0057;
OR 1.16; 95% CI [1.04–1.3]). Association of rs917997
with both CD and UC, and association of rs10870077
with both the UC and IBD groups, remained signiﬁcant af-
ter Bonferroni correction for the total number of 354 SNPs
included in phase I. Associations in the combined dataset
for CARD8 and REL genes were not signiﬁcant after correc-
tion for multiple testing.
In this study we performed a candidate screen of innate
immunity pathway genes in IBD and observed a strong as-
sociation with a common SNP located in the IL1RL1-
IL18R1-IL18RAP-SLC9A4 locus on chromosome 2q11-
2q12. Interestingly, association of the same allele of the
IL18RAP rs917997 gene with celiac disease (MIM 212750;
a distinct disorder but one that is also characterized by in-
testinal inﬂammation) has been reported in a recent GWAS
study22 and replicated in an independent cohort of celiac-
disease patients from three different populations.30
Replication of genetic ﬁndings in multiple populations
is an important step in establishing a genetic effect on dis-
ease predisposition. Recently a large genome-wide associa-
tion study was performed by theWellcome Trust Case Con-
trol Consortium (WTCCC). This study included 2,000 CD
patients and 3,000 controls from the UK.8 We investigated
publicly available WTCCC results for association of
IL1RL1-IL18R1-IL18RAP-SLC9A4 (rs917997) and CARD9
(rs10870077) in the UK CD cohort (WTCCC data accessed
on November 21, 2007). Neither SNP had been typed on
the Affymetrix platform, so only imputed genotypes were
available.31 In the WTCCC CD dataset, the rs917997
showed moderate association with the same allele (p ¼
9.19 3 104) (Table 5). The combined Cochran-Mantel-
Haenszel test of allelic association of rs917997 with
CD in the Dutch and UK (WTCCC) data resulted in an
even stronger association of this SNP with CD (p-value
(pM-H ¼ 8.63 3 109).
To ensure that association in the 2q11-2q12 region is
limited to the IL1RL1-IL18R1-IL18RAP-SLC9A4 locus, we
investigated the region of ~898 kb (Chr2:102040449–1206 The American Journal of Human Genetics 82, 1202–1210, May102947000) by including this and the neighboring LD
blocks from the GWAS WTCCC CD dataset. Among 238
SNPs that have been genotyped in the ~898 kb block, the
strongest association was observed with three SNPs, all of
which are located within the IL18RAP gene (Figure S1).
This strongly indicates that in the WTCCC data associa-
tion in CD is limited to the IL1RL1-IL18R1-IL18RAP-
SLC9A4 block itself, rather than being a side effect of asso-
ciation in the neighboring haplotype blocks.
Because of strong LD, ﬁne mapping within the IL1RL1-
IL18R1-IL18RAP-SLC9A4 locus is not possible by genetic
means. The ~350 kb LD block includes four genes, two of
which, IL18RAP and IL18R1, are receptors for the IL18 pro-
tein and were selected for our candidate-gene study. Re-
markably, a cis effect of the associated rs917997 on the
level of gene expression of the IL18RAP transcript was re-
cently observed in the celiac-disease study.30 This observa-
tion prioritizes the IL18RAP gene among its neighbors as
a candidate gene for IBD. The role of the IL18 protein in
CD is now being increasingly recognized. IL18 is mainly
produced by antigen-presenting cells and stimulates the
production of interferon-g and pro-inﬂammatory cyto-
kines such as TNF-a and IL-1b.32 Expression of IL18 is in-
creased in mucosal biopsies from IBD patients compared to
controls, and in involved versus non-involved lesions.33–35
Furthermore, IL18 mRNA levels are upregulated in intes-
tinal epithelial cells and lamina propria mononuclear cells
in CD patients, and the bioactive form of IL18 could only
be found in patients but not in controls.35,36 Finally, sev-
eral mouse models for CD show that blocking IL18 with
an IL18-binding protein attenuates the intestinal inﬂam-
mation.37,38 The IL18 receptor complex is expressed on in-
testinal epithelial cells and consists of the ligand-binding
chain (IL18R1, IL18Ra) and a signal-transducing chain
(IL18RAP, IL18Rb).39 IL18 receptors, in response to IL18,
activate the NF-kb pathway, which is a central element in
the pathogenesis of CD.2,33 The IL1RL1-IL18R1-IL18RAP-
SLC9A4 locus is therefore a very likely candidate for IBD
pathogenesis. Interestingly, SNPs in the IL18 gene also
tended to be associated with IBD in our initial screen
(p ¼ 0.0086, Table S1), although the association was only
moderate and needs further replication.
Another locus that shows association predominantly
with UC is located on 9q34.3 and includes the CARD9
gene, which encodes an adaptor molecule of PRR signal-
ing. CARD9 is an attractive candidate gene for IBD associ-
ation because it is essential in the process of stimulating
the innate immune signaling by intracellular and extracel-
lular pathogens.40 Three studies of CARD9-deﬁcient mice
showed that CARD9 is required for inducing the cytokine
response and for protection from fungal and bacterial in-
fection.41–44 Upon stimulation by intracellular pathogens,
CARD9 speciﬁcally interacts with NOD2, which leads to
increased cytokine production via activation of MAPK.43
Alternatively, stimulation of other PPR family molecules
by extracellular pathogens leads to NF-kb activation
through the syk-CARD9 interaction.45,46 One possible2008
Phase III IBD Cohort and in the Combined Dataset
ses Phases I, II, and III versus Controls Phases I, II, and III
AF P Value OR (95% CI)
327 0.028 0.88 (0.79–0.99)
282 6.31 3 107 1.36 (1.21–1.54)
473 5.70 3 103 1.16 (1.04–1.30)
355 0.759 1.02 (0.91–1.14)
315 0.005 0.83 (0.74–0.94)
278 2.46 3 105 1.34 (1.17–1.53)
497 4.03 3 105 1.28 (1.14–1.44)
383 0.030 1.15 (1.01–1.30)
322 0.002 0.86 (0.78–0.95)
28 1.90 3 108 1.35 (1.22–1.50)
484 3.25 3 105 1.21 (1.11–1.33)
366 0.166 1.07 (0.97–1.18)
d 1936 controls.
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7Table 4. Association of REL-rs842647, IL18RAP-rs917997, CARD9-rs10870077, and CARD8-rs10418239 SNPs in the
Control Phase III Cases Phase III versus Control Phase III Control Phases I, II, and III Ca
Name SNP Minor Allele MAF MAF P Value OR (95% CI) MAF M
Crohn’s Disease
rs842647 A; G G 0.357 0.320 0.067 0.85 (0.71–1.01) 0.355 0.
rs917997 G; A A 0.235 0.281 0.012 1.27 (1.05–1.54) 0.223 0.
rs10870077 C; G G 0.425 0.480 0.0093 1.25 (1.06–1.48) 0.436 0.
rs10418239 C; G G 0.367 0.354 0.534 0.95 (0.80–1.13) 0.351 0.
Ulcerative Colitis
rs842647 A; G G 0.357 0.339 0.402 0.93 (0.76–1.12) 0.355 0.
rs917997 G; A A 0.235 0.269 0.091 1.20 (0.97–1.48) 0.223 0.
rs10870077 C; G G 0.425 0.494 0.0034 1.32 (1.10–1.59) 0.436 0.
rs10418239 C; G G 0.367 0.366 0.95 0.99 (0.82–1.21) 0.351 0.
Inflammatory Bowel Disease (Crohn’s Disease þ Ulcerative Colitis)
rs842647 A; G G 0.357 0.328 0.090 0.88 (0.76–1.02) 0.355 0.
rs917997 G; A A 0.235 0.276 0.009 1.24 (1.05–1.46) 0.223 0.
rs10870077 C; G G 0.425 0.486 0.00081 1.28 (1.11–1.48) 0.436 0.
rs10418239 C; G G 0.367 0.359 0.649 0.97 (0.83–1.12) 0.351 0.
Phase III included 786 IBD cases (452 CD, 334 UC) and 768 controls. The combined analysis included 1851 IBD cases (1062 CD; 789 UC) an
Table 5. Association of rs917997 and rs10870077 with Crohn’s Disease in the WTCCC Data
SNP Quality Prediction MAF Controls MAF CD Cases P Value OR (95% CI)
rs10870077 0.8752 0.4172 0.4570 0.0002 1.18 (1.08–1.28)
rs917997 0.9993 0.2185 0.2483 0.0009 1.18 (1.07–1.30)mechanism for CARD9’s involvement in IBD pathogenesis
is via regulation of the IL17 response to the pathogens.
Activation of the syk-CARD9 complex via dectin-1 (the
C-type lectin molecule) promotes the maturation of den-
dritic cells, production of pro-inﬂammatory cytokines, in-
cluding IL23, and differentiation of T cells to TH-17 cells.
The process of differentiation of TH-17 cells under Candida
albicans infection is markedly reduced in CARD9/
cells.44 Interestingly, the current hypothesis on the role
of the recently described IL23R gene in IBD pathogenesis
also suggests an effect from IL23R mutations on TH-17
cell development.47,48 It is possible that mutations in
CARD9 and IL23R share a similar pathogenesis mechanism
for affecting the disease susceptibility.
A recent expression study on 400 blood samples of
asthma patients indicated a strong cis effect from a perfect
proxy of the CARD9 rs10870077 (rs4077515, r2¼ 1 in CEU
HapMap samples, and r2 ¼ 0.95 in Dutch controls) on
expression of CARD9 (effect rs4077515*G allele 0.538,
H2: 14.17, p value 1.1 3 1013) (‘‘mRNA by SNP
browser’’).33,49,50 This suggests that the rs10870077 geno-
type probably has a cis functional implication on CARD9
signaling via modiﬁcation of CARD9 expression.
In the WTCCC dataset, the CARD9 rs10870077 SNP was
less efﬁciently imputed (average maximum posterior call¼
0.87), probably as a result of the location of the gene on the
distal part of chromosome 9 and low coverage of this re-
gion by the genotyping platform. However, the imputed
results show an increased frequency of the minor
rs10870077*G allele in CD cases (45.7%), compared to
controls (41.7%) (p ¼ 1.75 3 104), which is consistent
with our observations for CD (Table 5). The combined
Cochran-Mantel-Haenszel test of CARD9 rs10870077
SNP with CD in the Dutch and WTCCC datasets indicates
moderate but consistent association to CD in both popula-
tions (p value (pM-H ¼ 1.20 3 106). In our dataset, the
CARD9 gene showed stronger association to UC than to
CD. Further replication of these data in international IBD
cohorts is necessary for estimating the effect of CARD9
locus polymorphisms on CD and UC.
In this study we selected the CARD9 as a functional can-
didate gene; however CARD9 is located in an extended
haplotype block spanning ~120 kb and also including
the following genes: GPSM1 (MIM 609491), LOC728489
(DNLZ), SNAPC4 (MIM 602777), SDCCAG3, PMPCA,
INPP5E, and KIAA0310 (SEC16A). The strong LD within
the block does not allow us to exclude other genes in the
region from association with IBD, and moreover, poor cov-
erage of this locus in the WTCCC dataset does not allow to
exclude the neighboring blocks (only 18 SNPs have been1208 The American Journal of Human Genetics 82, 1202–1210, Maytyped in the ~778 kb block including the CARD9 locus
and neighboring blocks in theWTCCC dataset). A number
of genes located in theCARD9 block are also attractive func-
tional candidates for association with IBD. The ﬁrst one to
mention, theGPSM1 genebelongs to activators ofGprotein
signaling and is known to play a regulatory role in autopha-
gosome formation in intestinal cells.51 Recent GWAS stud-
ies discovered the two autophagy genes, ATG16L1 and
IRGM, andhighlighted the important role of the autophagy
pathway in the pathogenesis of CD.52 Another plausible
functional candidate, SDCCAG3 (serologically deﬁned co-
lon cancer antigen 3), is involved in regulating expression
of the tumor necrosis factor (TNF) receptor on the cell sur-
face and in the anti-apoptotic mechanism during TNF sig-
naling. TNF is a widely expressed cytokine involved in in-
ﬂammation and innate immunity.53 Further investigation
of the CARD9 and surrounding genes is needed to verify
the true causative gene in the 9q34.3 locus.
In this study we performed a comprehensive analysis of
candidate genes from 85 genes in the innate-immunity
molecular pathway, in a group of 1851 IBD patients and
1936 controls, and discovered the IBD-susceptibility
gene locus that includes the IL1RL1-IL18R1-IL18RAP-
SLC9A4 genes on chromosome 2q11-2q12. We also
observed association of the CARD9 variant, located in
extended haploblock on 9q34.3, predominantly with
UC, although this latter ﬁnding needs further ﬁne
mapping and conﬁrmation.
Supplemental Data
One ﬁgure and two tables are available with this article online at
http://www.ajhg.org/.
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